In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: The azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study

Hypertension Research

Volumn 31, Issue 8, 2008, Pages 1499-1508

  Katayama, Shigehiro ^a   Kawamori, Ryuzo ^b   Iwamoto, Yasuhiko ^c   Saito, Ikuo ^d   Kuramoto, Kizuku ^e  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

Azelnidipine; Combination therapy; Hypertensive diabetics; Target blood pressure; Temocapril hydrochloride

Indexed keywords

8 ISOPROSTANE; ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZELNIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; POTASSIUM; TEMOCAPRIL;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SIDE EFFECT; STOMACH CANCER; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 55449086285     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1499     Document Type: Article

References (21)

1. Chobanian AV, Bakris GL, Black HR, et al; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
2. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
4. Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl): S1-S105.
5. Arauz-Pancheco C, Parrott MA, Raskin P, American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26 (Suppl 1): S80-S82.
6. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl 1): S1-S266.
7. Tatti P, Pahor M, Byington RP, et al: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
8. Katayama S, Kawamori R, Shimamoto K, Ogihara T, Kikkawa R: Collections and analysis of basic data for development of 'Therapeutic guideline for management of diabetic hypertension in Japan.' Ther Res 1998; 19: 2949-2968 (in Japanese).
9. Hansson L, Zanchetti A, Carruthers SG, et al, HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
10. Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R: Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601-605.
11. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M: Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
12. Singer GM, Izhar M, Black HR: Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002; 40: 464-469.
13. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T: Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-208.
14. Naito Y, Shimozawa M, Manabe H, et al: Anti-oxidative properties of a new calcium channel blocker azelnidipine. Prog Med 2004; 24: 2676-2681 (in Japanese).
15. Horiuchi M: Protective effects of azelnidipine and their enhancement by the combination with angiotensin II type 1 receptor blockers. Prog Med 2004; 24: 2682-2687 (in Japanese).
16. Hata T: Endothelial dysfunction in essential hypertension and temocapril. Prog Med 1999; 19: 1123-1128 (in Japanese).
17. Muso E, Takeda T, Suyama K: Specific renoprotective effect of temocapril (TEM), an ACE inhibitor with biliary excretion, in human and animal model of renal damages with massive proteinuria. Prog Med 1999; 19: 1138-1143 (in Japanese).
18. Fujimoto S, Sato M, Komai N, Kashihara N: Effects of azelnidipine on renal microcirculation. Prog Med 2004; 24: 2670-2675 (in Japanese).
19. Nakamura T, Sugaya T, Kawagoe Y, et al: Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: 321-326.
20. Fliser D, Buchholz K, Haller H, European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
21. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H: Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135-1140.